Public Policy Forum on Venture Capital and Innovation
2011 Program

 

The 2011 PPF will emphasize around the following elements (see detailed schedule below):

 

  1. Opening Keynote
  2. Dr Josh Lerner, Jacob H. Shiff Professor of Investment Banking at Harvard Business School, will set the stage. His opening remarks will lay out critical challenges facing the VC industry, important recent developments, and new ideas and approaches for public policies.

     

  3. Main topics
  4. Exits

    Growing evidence exists that beyond cyclicality, there are major structural problems in the IPO market, especially in the US which for decades has been the leading market for technology IPOs. This market has been in decline for more than ten years. Has the decline in the VC industry fuelled the IPO decline? Or is it the IPO decline that has fuelled the VC decline? As one of last year's participants said: "We are still struggling with company formation and company financing. But the real problem is with exits. Fix that and you fix everything. If we deliver the money back, we will get more of it". Or to put it another way, building value does little good if that value cannot be realized. And when it becomes clear that the value cannot be realized, does not that awareness erode the very "value building" process itself? How do we bring these chain reactions under control? Where do we begin? How do you measure the decline in the IPO market? What are its causes? What are the solutions, and what role will new public policies play in them? The Forum will confront these issues thanks to a panel of industry leaders and other experts and through a new Harvard Business Case on Chinext, the Shenzhen junior stock exchange on which there has been a boom of technology IPOs. How did this boom occur? Is it real? Can it last? And is this Chinese model applicable to other countries?

    Corporate sources of capital: lessons from the life science sector

    As traditional financial LPs turn their backs on venture capital, technology start-ups and VC funds must now look to alternative sources of capital. Corporations and their venture arms are one of them which is of particular importance as we witness a recrudescence of interest from corporations for this domain.

    Corporate venturing has a particularly rich history in the Life Science sector and large pharmaceutical companies have been particularly active recently to renew their approach and develop new models. This panel will focus on two recent examples in this sector as interesting case studies which may shed some light on the current wave of corporate venturing more generally.

    Creating a new technology environment: the case for Singapore

    Adequate supply of capital is only one part of a buoyant ecosystem for venture capital and emerging technology companies. Setting the environment right (R&D funding, legal, fiscal, intellectual property) and supporting the development of entrepreneurship and innovation are also key ingredients. Singapore's emerging technology cluster has developed initiatives in a short period of time to address these critical needs. How successful are its policies? What lessons can be learnt?

     

  5. Roundtable discussions among peers
  6. A one day Forum can only cover so many topics. To allow participants to interact with peers on other important topics of interest to them, a series of round tables (8-10 people) will be organized in advance and conducted by a moderator.

 

  • When: Monday, October 24, 2011

  • Location: Musée National des Beaux Arts du Québec (Museum of Fine Arts)

    The PPF will not be held at the Château Frontenac (the hotel) but at the Musée National des Beaux Arts du Québec (Museum of Fine Arts) which is about 10 minutes away by car and 30 minutes walking.

    Shuttles will pick up participants at the Chateau Frontenac every 10 minutes starting at 7:00 am. Gathering will take place in the lobby of the hotel.

  • A breakfast will be served at the Museum between 7:00 and 8:30



Monday, October 24 , 2011

8:30 to 8:50 am

WELCOME REMARKS

Mr. Stephen A. Hurwitz
Co-Founder and Chair
The Quebec City Conference
Bio »

Mr. Christian Racicot
Co-Founder and President
The Quebec City Conference

Bio »

Mr. Yigal Erlich
Founder, Chairman and Managing Partner
The Yozma Group

Chair
Public Policy Forum on Venture Capital
Bio »

INTRODUCTION

Dr. Gilles Duruflé
President
Public Policy Forum on Venture Capital
Bio »

8:50 to 9:50 am

KEYNOTE PRESENTATION

“Entrepreneurial Finance in the Broader Environment: Lessons from Challenging Times”

Dr. Josh Lerner
Jacob H. Schiff Professor of Investment Banking
Harvard Business School
Bio »

Dr. Thomas Hellmann
B.I. Ghert Family Foundation Professor in Finance and Policy
Sauder School of Business
, University of British Columbia
Bio »

9:50 to 10:50 am

FIRST PANEL

Subject:

Exits: Decline in IPO Markets – Causes, Solutions, New Public Policies

Moderator:

Mr. Stephen A. Hurwitz
Partner
Choate, Hall & Stewart, LLP
Co-Founder and Chair
The Quebec City Conference
Bio »

Panelists:

Mr. Jeffrey Bussgang
General Partner
Flybridge Capital Partners
Bio »

Ms. Anne Glover
Chief Executive
Amadeus Capital Partners
Member of the EVCA Stock Exchange Roundtable & Task Force
Bio »

Dr. William H. Janeway
Managing Director & Senior Advisor
Technology Media and Telecommunications

Warburg Pincus
Bio »

Ms. Kate Mitchell
Managing Director
Scale Venture Partners
Chair of the Small Company IPO Task Force
Bio »

10:50 to 11:10 pm

NETWORKING BREAK

11:10 to 12:15 pm

SECOND PANEL

Subject:

Corporations as Alternative Sources of Capital: New Models of Corporate Involvement in Venture Capital – Lessons from the Life Science Sector

Moderator:

Dr. Frank Landsberger
Senior Managing Director
INKEF Capital
Bio »

Panelists:

Mr. Laurent Arthaud
Deputy CEO
CDC Entreprises
Bio »

Dr. Hubert Birner
General Partner
TVM Capital
Bio »

Mr. Darren Carroll
Vice President - Corporate Business Development
Eli Lilly and Company

Bio »

Mr. Philippe Tcheng
Vice President, Public and Government Affairs France
Sanofi Aventis
Chairman of the Strategic Committee
Innobio Fund
Bio »

12:15 to 1:30 pm

NETWORKING LUNCH

1:30 to 2:15 pm

THIRD PANEL

Subject:

Setting the Environment Right: Lessons Learnt from the Singapore Experience

Interviewer :

Mr. Yigal Erlich
Founder, Chairman and Managing Partner
The Yozma Group

Chair
Public Policy Forum on Venture Capital
Bio »

Panelist:

Mr. Cheong Boon Png
Chief Executive
Spring

Bio »

2:15 to 3:45 pm

HARVARD BUSINESS CASE

Subject:

Oriental Fortune Capital: Building a Better Stock Exchange – The Case of ChiNext, the Shenzhen Junior Market

Case Researchers:

Dr. Josh Lerner
Jacob H. Schiff Professor of Investment Banking
Harvard Business School
Bio »

Mr. Keith Chi-ho Wong
Senior Researcher
HBS-Asia Pacific Research Center


3:45 to 4:00 pm

NETWORKING BREAK

4:00 to 4:55 pm

ROUNDTABLES

Participants will be invited to choose their table in advance among the following themes:

Theme 1: Are new incentives needed to attract private sector investors back to venture capital? If so, which ones are the best? Several countries have shown renewed interest in guarantee schemes and protection against first losses. Will these approaches work?

Theme 2: In many countries, venture capital funds are subscale in size and expertise. Are cross-border funds a way to address this issue? If so, how can they be created and funded?

Theme 3: More and more countries are considering policies to support business angel investment: what are the best examples of these new policies? The worst? Which will work, and why?

Theme 4: Can government agencies and other public entities attract and retain the talent needed to implement programs to support venture capital and innovation, in the absence of an ability to pay them compensation at private industry level? How is this problem solvable?

Theme 5: What is the role of growth equity in building an entrepreneurial ecosystem in emerging markets? Will that growth equity be available?

Theme 6: What new fund models will align interests of LPs and GPs, including in the many ecosystems other than Silicon Valley? What are the most promising new developments?

Theme 7: Technology transfer from universities and research centers: who owns the IP? Who should own the IP? Who should do the transfer, and under which terms? What universities are doing it right? MIT? Harvard? Oxford? Toronto?

4:55 to 5:00 pm

CLOSING REMARKS

Dr. Josh Lerner and Dr. Gilles Duruflé

5:00

All attendees are invited to the Quebec City Conference immediately following